Studies related to Symptoms of Schizophrenia and Sarcosine

Glycine Transporter I Inhibitor, N-methylglycine (sarcosine), Added To Clozapine For The Treatment Of Schizophrenia

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 20
Gender Both Genders
Age Range 30-44
Notes for this study:
In persons on clozapine, supplementation of sarcosine at 2,000mg daily for 6 weeks has failed to significantly improve symptoms. This is thought to be due to an incompatability with clozapine and additional serinergic/glycinergic signalling rather than a per se fault of sarcosine.

A Randomized, Double-blind, Placebo-controlled Comparison Study Of Sarcosine (N-methylglycine) And D-serine Add-on Treatment For Schizophrenia

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 60
Gender Both Genders
Age Range 30-44, 45-64
Notes for this study:
Sarcosine at 2,000mg daily for 6 weeks in persons with schizophrenia on stable antipsychotic therapy was able to reduce symptoms of schizophrenia (positive, negative, and cognitive) while the comparator of D-serine at the same dose was ineffective.

Sarcosine Or D-serine Add-on Treatment For Acute Exacerbation Of Schizophrenia: A Randomized, Double-blind, Placebo-controlled Study

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 65
Gender Both Genders
Age Range 30-44, 45-64
Notes for this study:
Six weeks of sarcosine therapy at 2,000mg daily in persons with schizphrenia on stable antipsychotic therapy was able to bring additional benefits to all symptomology, whereas the reference drug D-serine was ineffective.

Glycine Transporter I Inhibitor, N-methylglycine (sarcosine), Added To Antipsychotics For The Treatment Of Schizophrenia

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 38
Gender Both Genders
Age Range 18-29, 30-44
Notes for this study:
2,000mg of sarcosine daily for 6 weeks in schizophrenics on stable antipsychotic therapy was able to reduce all symptoms associated with schizophrenia in the range of 14-16%.
Funding issues for this study:
No funding issue, but Guochuan Tsai is the creator of sarcosine